HighTower Advisors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
F
HighTower Advisors's NVO Position: Q2 2026 in Review
HighTower Advisors increased its Novo Nordisk (NVO) stake by 72% in Q2 2026, buying an estimated $7.23M and bringing the position to 403,262 shares worth $19.3M. The position accounts for 0.02% of the portfolio, ranked #659.
HighTower Advisors first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $72.9M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- HighTower Advisors held 403,262 shares of Novo Nordisk worth $19.3M as of Q2 2026.
- HighTower Advisors bought 168,196 Novo Nordisk shares in Q2 2026, an estimated $7.23M.
- Novo Nordisk made up 0.02% of HighTower Advisors's portfolio in Q2 2026, its #659 holding.
- HighTower Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
- HighTower Advisors's Novo Nordisk position peaked at $72.9M in Q2 2024.
- 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.